Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

ENDP

Endo (ENDP)

Endo International PLC
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ENDP
日付受信時刻ニュースソース見出しコード企業名
2023/09/2120 : 45PR Newswire (Canada)Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual MeetingNASDAQ:ENDPEndo International PLC
2023/09/2120 : 45PR Newswire (US)Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual MeetingNASDAQ:ENDPEndo International PLC
2023/08/0820 : 45PR Newswire (US)ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
2023/08/0820 : 45PR Newswire (Canada)ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
2023/07/1905 : 30PR Newswire (US)Endo Launches Bivalirudin Injection in Ready-to-Use VialsNASDAQ:ENDPEndo International PLC
2023/07/1405 : 30PR Newswire (US)Endo Presents New Data at the American Podiatric Medical Association Annual MeetingNASDAQ:ENDPEndo International PLC
2023/06/3005 : 31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
2023/06/1220 : 30PR Newswire (US)Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled SyringeNASDAQ:ENDPEndo International PLC
2023/06/1220 : 30PR Newswire (US)Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled SyringeNASDAQ:ENDPEndo International PLC
2023/06/1220 : 30PR Newswire (Canada)Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled SyringeNASDAQ:ENDPEndo International PLC
2023/05/0820 : 37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
2023/05/0820 : 30PR Newswire (US)ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
2023/04/1720 : 45PR Newswire (US)Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label ProgramNASDAQ:ENDPEndo International PLC
2023/04/0405 : 30PR Newswire (Canada)Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral SuspensionNASDAQ:ENDPEndo International PLC
2023/04/0405 : 30PR Newswire (US)Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral SuspensionNASDAQ:ENDPEndo International PLC
2023/03/1405 : 17PR Newswire (US)Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar FibromatosisNASDAQ:ENDPEndo International PLC
2023/03/1021 : 30PR Newswire (US)Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) CapsulesNASDAQ:ENDPEndo International PLC
2023/03/0706 : 14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ENDPEndo International PLC
2023/03/0623 : 32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
2023/03/0623 : 28Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
2023/02/2807 : 15Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ENDPEndo International PLC
2023/02/2807 : 10Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ENDPEndo International PLC
2023/02/2807 : 05Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ENDPEndo International PLC
2023/02/2807 : 00Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:ENDPEndo International PLC
2023/02/1423 : 00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
2023/02/1402 : 39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ENDPEndo International PLC
2023/02/0621 : 30PR Newswire (US)Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's DiseaseNASDAQ:ENDPEndo International PLC
2023/02/0107 : 06Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:ENDPEndo International PLC
2022/12/2306 : 24Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
2022/12/0706 : 45PR Newswire (US)Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)NASDAQ:ENDPEndo International PLC
 Showing the most relevant articles for your search:NASDAQ:ENDP